Drug
Durvalumab 50 MG/ML
Durvalumab 50 MG/ML is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
2(50%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
1
25%
Ph phase_2
3
75%
Phase Distribution
1
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
3(75.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Completed(1)
Other(1)
Detailed Status
Completed1
Recruiting1
Active, not recruiting1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (25.0%)
Phase 23 (75.0%)
Trials by Status
completed125%
recruiting125%
active_not_recruiting125%
unknown125%
Recent Activity
2 active trials
Showing 4 of 4
recruitingphase_2
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
NCT07149363
active_not_recruitingphase_1
Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab
NCT04748419
completedphase_2
Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer
NCT04156087
unknownphase_2
RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus
NCT04159974
Clinical Trials (4)
Showing 4 of 4 trials
NCT07149363Phase 2
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
NCT04748419Phase 1
Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab
NCT04156087Phase 2
Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer
NCT04159974Phase 2
RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4